Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 801-694-5 | CAS number: 1392325-86-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
No experimental toxico-kinetic data are available for assessing adsorption, distribution, metabolisation and excretion of the substance. Based on effects seen in the human health toxicity studies and physico-chemical parameters AmberTonic is expected to be readily absorbed via the oral route and somewhat lower via the inhalation and dermal route. Based on available in vivo data the absorption percentages derived are: 100% oral absorption, 15% dermal absorption and 31.2% inhalation absorption.
Key value for chemical safety assessment
- Bioaccumulation potential:
- low bioaccumulation potential
- Absorption rate - oral (%):
- 100
- Absorption rate - dermal (%):
- 15
- Absorption rate - inhalation (%):
- 31.2
Additional information
Toxico-kinetic behaviour of AmberTonic
Introduction
The test material AmberTonic (CAS no. 1356400-59-3 and 1356399-98-8) is a quinazoline type of substance with an additional ring structure containing 5 carbons and 5 methyl groups. It is a solid with a molecular weight of 244.38 that does not preclude absorption. The test material contains no hydrolysable groups. The substance has a low volatility with a vapour pressure of 0.029 Pa.
Absorption
Oral:The results of the acute and repeat dose oral toxicity studies of the substance show that the substance is being absorbed by the rat gastro-intestinal tract following oral administration. In the acute oral toxicity study mortality was seen. In the repeated dose toxicity study adverse effects were seen on liver and kidney relating to hypertrophy and periportal vacuolation in the liver and alpha 2µ-globulin nephropathy in the kidney. The relatively low molecular weight and the moderate octanol/water partition coefficient (Log Kow 5.43) and water solubility (9.82 mg/l) would favour absorption through the gut. According to Martinez and Amidon (2002) the optimal log Kow for oral absorption falls within a range of 2-7. This indicates that AmberTonic is likely to be absorbed orally and therefore the oral absorption is expected to be 100%.
Skin: Based on the physico-chemical characteristics of the substance, being a solid, its molecular weight (244.38), log Kow (5.43) and water solubility (9.82 mg/L), indicate that limited dermal absorption is likely to occur. The optimal MW and log Kow for dermal absorption is < 100 and in the range of 1-4, respectively (ECHA guidance, 7.12, Table R.7.12-3). AmberTonic is just outside optimal range. Dermal absorption can be derived from acute oral versus acute dermal toxicity data. In view of the mortality seen at 2000 and 300 mg/kg bw in the acute oral toxicity test and absence of mortality in the acute dermal toxicity test at 2000 mg/kg bw, the dermal absorption is at least 6.7 (2000/300) lower compared to oral absorption. Assuming oral absorption to be 100%, this will result in a dermal absorption of 15%.
Lungs: Absorption via the lungs is also indicated based on physico-chemical properties. Though the inhalation exposure route is thought minor, because of its low volatility (0.029 Pa), the octanol/water partition coefficient (5.43), indicates that inhalation absorption is possible.Inhalation absorption can be derived from acute oral versus acute inhalation toxicity data. According to ECHA guidance on CLP, 1 mg/kg bw is equal to 0.0052 mg/L/4h. This means at 961 mg/kg bw (5/0.0052) no inhalation toxicity was observed. The inhalation absorption is at least 3.2 (961/300) lower compared to oral absorption. Assuming oral absorption to be 100%, this will result in inhalation absorption of 31.2%.
Distribution
The moderate water solubility of the test substance would limit distribution in the body via the water channels. The log Kow would suggest that the substance would pass through the biological cell membrane. Due to the predicted metabolisation the substance as such is not expected to accumulate in the body fat significantly.
Metabolism
There are no actual data on the metabolisation of AmberTonic. Considering the pyrimidine ring with two nitrogens the substance can be protonated on these nitrogens under acidic conditions. This protonated AmberTonic has a low pKa meaning that the H atom will be removed again under less acidic conditions. After oral exposure the substance may be protonated in the stomach and deprotonated in the stomach and gut. The irritation properties of the substance in the stomach may be related to this. In the liver, considering P450 metabolism, the following steps are predicted by ToxTree (v 3.1.0.1851); aliphatic hydroxylation at position 1 or 2: N-oxidation at position 3; aliphatic hydroxylation at position 4 are anticipated (see Fig. 1). It is likely that the hydroxylation of the cyclohexyl ring occurs because this will be the site of attack for glucuronidation and possibly when overloaded it will be the site of attack for alpha-2u-globulin (expert judgment). The alpha-2u globulin nephropathy seen in the kidneys support this effect.
Fig. 1 The metabolisation pathway of the substance is presented (Toxtree version 3.1.0.1851).
Excretion
The route of excretion of the substance and its metabolites is via the urine and/or faeces. Any unabsorbed substance will be excreted via the faeces.
Discussion
The substance is expected to be readily absorbed orally, based on the human toxicological information and physico-chemical parameters. The substance also is expected to be absorbed dermally and via inhalation based on the physico-chemical properties, although the MW and the log Kow are higher than the favourable range.
The IGHRC (2006) document of the HSE and mentioned in the ECHA guidance Chapter 8 will be considered for deriving the final absorption values for the risk characterisation.
In view of the mortality seen in the acute oral toxicity at 300 and 2000 mg/kg bw (1/5 and 3/5) and absence of toxicity via the dermal and inhalation route: > 2000 mg/kg bw and > 5110 mg/m3 more specific absorption percentages can be derived.
Oral to inhalation extrapolation: Though the substance is not a volatile the inhalation exposure will be considered. The substance is not corrosive for skin and eye and the systemic effect will overrule the effects at the site of contact. In the presence of acute oral and inhalation data inhalation absorption can be estimated:According to ECHA guidance on CLP, 1 mg/kg bw is equal to 0.0052 mg/l/4h. This means at 961 mg/kg bw (5/0.0052) no inhalation toxicity was observed. The inhalation absorption is at least 3.2 (961/300) lower compared to oral absorption. Assuming oral absorption to be 100%, this will result in inhalation absorption of 31.2%.
Dermal absorption: can be derived from acute oral versus acute dermal toxicity data. In view of the mortality seen at 2000 and 300 mg/kg bw in the acute oral toxicity test and absence of mortality in the acute dermal toxicity test at 2000 mg/kg bw. The dermal absorption is at least 6.7 (2000/300) lower compared to oral absorption. Assuming oral absorption to be 100%, this will result in a dermal absorption of 15%.
Conclusion
AmberTonic is expected to be readily absorbed via the oral route and lower via the dermal and inhalation route based on physico-chemical and toxicity data. Based on available data the absorption percentages derived are: 100% oral absorption, 15% dermal absorption and 31.2% inhalation absorption. Bioaccumulation potential is expected to be low.
References
Martinez, M.N., And Amidon, G.L., 2002, Mechanistic approach to understanding the factors affecting drug absorption: a review of fundament, J. Clinical Pharmacol., 42, 620-643.
IGHRC, 2006, Guidelines on route to route extrapolation of toxicity data when assessing health risks of chemicals,http://ieh.cranfield.ac.uk/ighrc/cr12[1].pdf
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.